On Wednesday, Gilead Sciences GILD will release its latest earnings report. Benzinga's outlook for Gilead Sciences is included in the following report.
Earnings and Revenue
Gilead Sciences EPS is expected to be around $1.56, according to sell-side analysts. Sales will likely be near $5.2 billion.
Gilead Sciences EPS in the same period a year ago totaled $2.56. Sales were $7.14 billion. If the company were to match the consensus estimate when it reports Wednesday, earnings would be down 39.06 percent. Sales would be down 27.18 percent from the same quarter last year. Here's how the company's reported EPS has compared to analyst estimates in the past:
| Quarter | Q1 2018 | Q4 2017 | Q3 2017 | Q2 2017 |
| EPS Estimate | 1.64 | 1.67 | 2.12 | 2.13 |
| EPS Actual | 1.48 | 1.78 | 2.27 | 2.56 |
Stock Performance
Over the last 52-week period, shares are up 5.27 percent. Given that these returns are generally positive, long-term shareholders are probably content going into this earnings release. Analysts have adjusted their estimates lower for EPS and revenues over the past 90 days. The average rating by analysts on Gilead Sciences stock is a Neutral. The validity of this rating has maintained conviction over the past 90 days.
Conference Call
Gilead's conference call is scheduled to begin at 8:00 a.m. ET and can be accessed here: http://investors.gilead.com/phoenix.zhtml?c=69964&p=irol-fundsnapshot
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
